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Abstract
Objective
The gut microbiota has been designated as an active regulator of glucose metabolism and
metabolic phenotype in a number of animal and human observational studies. We evalu-
ated the effect of removing as many bacteria as possible by antibiotics on postprandial
physiology in healthy humans.
Methods
Meal tests with measurements of postprandial glucose tolerance and postprandial release
of insulin and gut hormones were performed before, immediately after and 6 weeks after a
4-day, broad-spectrum, per oral antibiotic cocktail (vancomycin 500 mg, gentamycin 40 mg
and meropenem 500 mg once-daily) in a group of 12 lean and glucose tolerant males. Fae-
cal samples were collected for culture-based assessment of changes in gut microbiota
composition.
Results
Acute and dramatic reductions in the abundance of a representative set of gut bacteria was
seen immediately following the antibiotic course, but no changes in postprandial glucose
tolerance, insulin secretion or plasma lipid concentrations were found. Apart from an acute
and reversible increase in peptide YY secretion, no changes were observed in postprandial
gut hormone release.
Conclusion
As evaluated by selective cultivation of gut bacteria, a broad-spectrum 4-day antibiotics
course with vancomycin, gentamycin and meropenem induced shifts in gut microbiota
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Introduction
The human gut is populated by a dense community of microbes (the gut microbiota) that
many-fold outnumbers our eukaryotic cell count and provides the host with an enormous
complimentary microbial gene set (the gut microbiome). Several metabolic disease states such
as obesity and type 2 diabetes have been linked with alterations in the microbiota composition
and function [1–3], and in animal models, it has been demonstrated that the microbiota
actively contributes to a number of host metabolic pathways such as energy harvesting poten-
tial, regulation of gut hormone secretion and nutrient storage [4–6].
Antibiotics cause marked short-term disturbances in the human gut microbiota, and incom-
plete recovery of the microbiota to its initial composition has been found in some patients fol-
lowing antibiotic treatment [7–10]. In observational studies, exposure to antibiotics has been
linked with development of obesity and type 2 diabetes [11–13]. Moreover, a 7-day course of
vancomycin, but not ampicillin, was followed by a reduction in peripheral insulin sensitivity in
a randomized controlled trial [14]. Increased body mass index (BMI) and altered levels of
appetite regulating gut hormones were found following antibiotic eradication ofHelicobacter
pylori in a cohort of patients referred to upper endoscopy [15]. Decreased insulin sensitivity
following a one-week antibiotic course with vancomycin was reported in obese males with met-
abolic syndrome, whereas no change in insulin sensitivity was observed following administra-
tion of amoxicillin for one week [16]. Thus, antibiotics seem to possess the potential to affect
host metabolism by altering the gut microbiota configuration, while the physiological impor-
tance and potential clinical implications of antibiotic-induced microbiota alterations remain to
be demonstrated.
We designed a prospective clinical study in order to elucidate how a short-term broad-spec-
trum antibiotics course targeting intestinal bacteria affects postprandial physiology in healthy
glucose tolerant male adults.
Methods
Study approval and registration
The study was approved by the Ethical Committee in the Capital Region of Denmark (H3-
2011-144, S1 File and S1 Protocol) and registered on clinicaltrials.gov (NCT01633762),
although the subject enrolment began 4 months before registration on clinicaltrials.gov
(unawareness). The study was conducted according to the principles of the Helsinki Declara-
tion II and written informed consent was obtained from all study participants.
Study design
In addition to a screening visit the study design encompassed 5 study visits (day 0, 4, 8, 42 and
180) and a 4-day 3-drug antibiotic course (see below) between the first 2 study visits (day 0 and
4) composed to eradicate as many gut bacteria as possible (S1 Fig). At all 5 study visits,
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bodyweight, height and blood pressure were measured, health questionnaires were completed
and fasting blood samples and a faecal sample were collected. In addition, on 3 of the study
days (day 0, 4 and 42) a standardised meal test with repeated blood sampling was performed.
Except from keeping the diet unaltered throughout the study period, and avoiding yoghurt
products on the 4 days preceding each visit, no dietary regulations were required.
Participants
Twelve healthy male volunteers were recruited (between March and September 2012) using the
following inclusion criteria: age 18–40 years, Caucasian ethnicity, informed written consent,
glycated haemoglobin A1c (HbA1c)<43 mmol/mol (<6.1%), normal bowel function (bowel
movements 1-3/day) and fasting plasma glucose (FPG)<6.0 mmol/l. Exclusion criteria
included any use of antibiotics 6 months prior to inclusion, BMI<18.5 kg/m2 or>25 kg/m2,
smoking, abnormal serum/plasma levels of electrolytes, lipids, creatinine, liver enzymes (ala-
nine transaminase, aspartate aminotransferase, alkaline phosphatase), thyroid stimulating hor-
mone or haemoglobin, any current or existing disease in the gastrointestinal system or family
history of inflammatory bowel disease or diabetes, lactose intolerance or coeliac disease, allergy
against the used antibiotics or use of medication that could not be paused during the study
period. Subjects had a mean age of 23.4 years (standard deviation 5.3 years) at the start of the
study.
Study visits
Study visits were conducted between April 2012 (first participant, first visit) and April 2013
(last participant, last visit). At all 5 visits, study participants arrived in the laboratory in the
morning after an overnight fast, having avoided strenuous physical exercise and alcohol con-
sumption for the last 24 h. Participants’ height and weight were measured after voiding.
On study visits days 0, 4 and 42 standardised liquid meal tests were performed: Participants
were sitting in a semi recumbent position in a hospital bed, blood pressure was measured
(Microlife BP A100, Microlife, Widnau, Switzerland), an intravenous catheter was inserted in a
cubital vein for collection of blood samples and the catheterised forearm was wrapped in a
heating pad (50°C) throughout the experiment in order to arterialise the venous blood. After
baseline sampling, participants ingested, within 5 minutes, a 2,205 kJ-liquid mixed meal
(Nutridrink, Nutricia, Allerød, Denmark) with 64.4 g carbohydrate, 20.3 g fat, 21.0 g protein,
and, for evaluation of gastric emptying, 1.5 g paracetamol. Blood samples were drawn 30, 15,
and 0 minutes before and 15, 30, 45, 60, 75, 90, 120, 150, 180, 210 and 240 minutes after inges-
tion of the mixed liquid meal. For bedside measurement of plasma glucose concentrations,
blood was added to fluoride tubes and centrifuged immediately at 7,400 g for 2 minutes at
room temperature. For measurements of gut hormone concentrations in plasma, blood was
collected in chilled tubes containing ethylenediaminetetraacetic acid (EDTA) and a specific
dipeptidyl peptidase 4 (DPP-4) inhibitor (valine-pyrrolidide, a gift from Novo Nordisk A/S,
Bagsværd, Denmark; final concentration in sample: 0.03 mmol/l). For the analyses of insulin
and C-peptide blood was sampled in dry tubes, which were left to coagulate for 20 minutes at
room temperature before centrifugation. For the analyses of C-reactive protein (CRP) and lip-
ids, blood was collected in lithium-heparin tubes. All samples were centrifuged for 20 minutes
at 1,200 g and 4°C except for one EDTA tube for the analysis of HbA1c. Plasma and serum
from day 0, 4 and 42, respectively, were stored at -20°C until analysis, whereas plasma from
day 8 and 180, for practical reasons, was stored at -80°C. Resting metabolic rate was measured
from time 210 to 225 min after meal intake by indirect calorimetry using a tight facemask con-
nected to a calorimeter, which measures the gas exchange breath-by-breath via an O2 alkali cell
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and an infrared CO2 sensor (CCMexpress1, Medgraphics, St. Paul, Minnesota, USA). Meta-
bolic rates are represented as averages of measures carried out every 10 second over the 15 min-
ute-period. Gallbladder dimensions were determined by ultrasound examination before, 25,
55, 90 and 235 minutes after meal intake using a 3.5 MHz-transducer (Logiq 9, GE Healthcare,
Little Chalfont, UK). Appetite ratings (hunger, fullness, desire to eat, nausea, bloating and
thirst) were assessed using validated visual analogue scales (VASs) [17,18] at baseline and with
30 minute-intervals during the meal test as previously described [18]. At time point 270 min,
participants were served a standardised solid ad libitummeal consisting of minced meat, pasta,
corn, carrots, and green pepper (5.9 g fat/100 g, 5.6 g protein/100 g, and 17.2 g carbohydrate/
100 g, corresponding to 6.1 kcal/g). The participants were instructed to eat until they felt pleas-
antly satiated and intake was measured as the difference between the weight of the served meal
and the remaining food. This test has been validated to reproduce spontaneous food intake
[19].
On study visits day 8 and 180, blood pressure was measured in the sitting position (Micro-
life BP A100, Microlife, Widnau, Switzerland) and a blood sample was taken from a cubital
vein.
Antibiotics treatment
At the end of the day 0 meal test, participants ingested an antibiotic ‘cocktail’ containing 500
mg meropenem (powder for infusion; Farmaplus, Oslo, Norway), 500 mg vancomycin (powder
for infusion; Fresenius Kabi, Bad Homburg, Germany) and 40 mg gentamicin (solution for
injection; Sandoz, Basel, Switzerland) dissolved in 150 ml of apple juice. The ‘cocktail’ was a
modified version of previous protocols used for prophylactic treatment of intensive care unit
patients [20,21]. It was designed to eradicate as many gut bacteria as possible with the lowest
possible risk of side effects. None of the 3 types of antibiotics are absorbed by the healthy
mucosa, and therefore have no direct effects on metabolism [22–24]. On day 1, 2 and 3, partici-
pants ingested the same antibiotic ‘cocktail’ at the same time of the day.
Collection of faecal samples
The day before each of the 5 study visits, the participants collected a faecal sample into a vial
(Sarstedt feces tube, 76 × 20 mm, Sarstedt, Nümbrecht, Germany), which was placed in a trans-
port container (Sarstedt, Nümbrecht, Germany) and stored in the participant’s own -20°C
freezer overnight. During the transportation to the hospital, the sample was kept frozen in a
thermo bag with 2 ice packs, and upon arrival in the laboratory, the sample was immediately
transferred to a -80°C freezer.
Evaluation of diet, gastrointestinal function and health-related symptoms
At each of the 5 study days, participants completed a standardised questionnaire about their
intake of common food items, number of bowel movements per day and stool consistency
(Bristol Stool Scale, with a value above 4 defined as loose stool [25]) on each of the 4 preceding
days. Diarrhoea was defined according to World Health Organization (3 loose stools per day
[26]). Participants were given a personal dairy and were asked to note any health-related symp-
tom, use of medication or change in activity or eating habits throughout the study period.
Laboratory methods
Plasma glucose was measured by the glucose oxidase method, using a glucose analyzer (Yellow
Springs Instrument model 2300 STAT plus analyzer; YSI, Yellow Springs, Ohio, USA). Serum
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insulin and C-peptide concentrations were measured using a 2-sided direct chemiluminescence
immunoassay (ADVIA Centaur XP; Siemens, Erlangen, Germany). Plasma CRP was measured
using an immunochemical assay, with a high-sensitive test used for CRP levels below 9.00 mg/l
(Vitros 5.1 FS; Ortho Clinical Diagnostics, Johnson & Johnson Medical, Birkerød, Denmark).
Plasma lipids (total cholesterol, high-density lipoprotein (HDL), and triglyceride) and paracet-
amol were quantified using an enzymatic colorimetric assay (Vitros 5.1 FS; Ortho Clinical
Diagnostics, Johnson & Johnson Medical, Birkerød, Denmark). By use of Friedewald’s formula
very-low-density lipoprotein (VLDL) was calculated from the amount of triglycerides multi-
plied by 0.45 and low-density lipoprotein (LDL) from the amount of total cholesterol minus
the amount of HDL and VLDL. HbA1c was measured by high Performance Liquid Chromatog-
raphy (Variant II TURBO, Bio-Rad, Hercules, California, USA). Plasma concentrations of
cholecystokinin (CCK), glucose-dependent insulinotropic polypeptide (GIP), glucagon-like
peptide-1 (GLP-1) and gastrin were measured by specific radioimmunoassays, as previously
described [27–29]. Peptide YY (PYY)3-36 (the major circulating molecular form of PYY
generated by DPP-4 mediated degradation of PYY1-36) was measured by a commercial radio-
immunoassay (cat#PYY-67HK, Milipore, Billerica, Massachusetts, USA) according to the man-
ufacturer’s recommendations. All quality controls were within acceptable limits.
Enumeration of bacteria in faecal samples was performed by the plate counting method.
From partially thawed faecal samples 0.1 g was transferred to 0.9 ml maximum recovery dilu-
ent and a 10-fold dilutions series was prepared and plated on 5 different agar media for enu-
meration of colony forming units (CFU). Plate count agar, McConkey agar No. 3 and Slanetz
and Bartley agar (Oxoid, Roskilde, Denmark) were used for enumeration of total aerobic
bacteria (and facultative anaerobes), Coliform bacteria and Enterococci respectively following
aerobic incubation at 37°C for 1, 2 or 3 days. Wilkins-Chalgren agar (Oxoid) and BSM agar
(Sigma-Aldrich, Brøndby, Denmark) were used for enumeration of total anaerobic bacteria
and bifidobacteria following incubation in an anaerobic chamber for 2 or 3 days. The choice of
the 3 specific bacterial groups was based on their taxonomic diversity (belonging to 3 different
phyla) and their natural presence in the human gut microbiota.
Concentration of vancomycin and gentamicin in faecal samples was determined by chemi-
luminescent immunoassay (Architect c4000, Abbott, Chicago, Illinois, USA) [30], while faecal
concentrations of meropenem were measured indirectly using an agar-cup assay [31].
Calculations and statistical analysis
Statistical analyses were carried out using SAS 9.3 (SAS Institute, Cary, North Carolina, USA).
Results are reported as means and 95% confidence intervals (CI) unless otherwise stated. For
comparison of differences between baseline value and day 4, 8, 42 and 180 values, the PROC
MIXED procedure was applied with participant and day as class variables, participant as ran-
dom effect and day 0 value (baseline) as reference. Faecal bacterial counts, lipid measurements
and all tAUC values were log10-transformed in order to improve the fit to the model. Test for
interaction between day and time was performed in order to see if the relationship between
time and postprandial excursions of glucose, pancreatic hormones and gut hormones were dif-
ferent on day 0, 4 and 42. If no interaction was detected, postprandial excursions of glucose,
insulin and gut hormones were summarised into area under the curve (AUC) values, calculated
using the trapezoidal rule and presented as total AUC (tAUC) values.
Gallbladder volume (V) was expressed in cm3 and calculated using the ellipsoid formula:
V = 1/6 πabc, where a = maximum length, b = maximum width, and c = maximum depth, as
described previously [32]. Matsuda index of insulin sensitivity, insulinogenic index and oral
disposition index were calculated as described previously [33–35]. Homeostasis model
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assessments of insulin resistance (HOMA2-IR) was calculated using the HOMA Calculator
version 2013 (http://www.dtu.ox.ac.uk, accessed July 2014). An indirect measure of gastric
emptying rate was obtained by calculating time-to-peak of plasma acetaminophen
concentration.
Results
Participants
Antibiotic treatment did not result in any serious or unexpected adverse events. During the
treatment period, loose stools were frequent and 9 of 12 participants had diarrhoea on 1 or
more of the 4 treatment days as shown in Fig 1. None of the 12 participants reported diarrhoea
on day 4 when the second meal test was conducted, and gastrointestinal symptoms (mild
abdominal pain and loose stools for a few days) were only reported by 1 participant during day
8 to day 180 (day 25–27).
No changes in bodyweight were observed between day 0 and day 4, 8 or 42, but a small
increase in mean bodyweight from 78.1 (73.9–82.4) to 79.4 (78.2–80.6) kg was seen from day 0
to day 180 (p = 0.04) with a corresponding increase in mean BMI from 22.6 (21.3–23.8) to 22.9
(21.3–23.8) kg/m2 (p = 0.04) (Table 1). There were no changes in mean blood pressure. No
health complaints or symptoms were reported during the study period, apart from a case of
epididymitis (treated with per oral doxycycline for 3 days on day 26–28 of the study), a com-
mon cold and the above-mentioned gastrointestinal symptoms.
Blood samples taken in the fasting state
No change from baseline in FPG or HbA1c was seen and no changes in plasma concentrations
of total cholesterol, LDL, HDL, VLDL or triglyceride were seen on the meal test days (day 0, 4
and 42). The basal concentrations of total cholesterol and LDL were slightly higher on day 8
Fig 1. Number of participants reporting loose stools and diarrhoea in the days before, during and immediately after the antibiotics course. Loose
stools are defined as stool consistency on the Bristol Stool Scale chart of >4. Diarrhoea was defined as 3 or more loose stools per day. All participants had
loose stools after having received the antibiotic course for 3 days.
doi:10.1371/journal.pone.0142352.g001
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and 180 compared to day 0 (p<0.05), with no significant changes in triglyceride concentrations
(Table 1). The plasma concentration of CRP was below 3 mg/l in 59 of the 60 samples, and was
unchanged by the antibiotic course (Table 1).
Cultivation of faecal samples
As shown in Fig 2, the total anaerobic bacterial count decreased from 8.5 (7.9–9.0) log10 CFU/g
before antibiotics to 6.2 (5.5–6.9) log10 CFU/g immediately following the antibiotic course
(p<0.0001). Enterococci, coliforms and bifidobacteria also decreased markedly following the
antibiotic course (falling from 4.2, 4.6 and 7.1 log10 CFU/g, respectively, on day 0, to below the
detection limit on day 4 (p<0.01 for all groups)). On day 8, the abundance of aerobic (and fac-
ultative anaerobic) bacteria, enterococci and coliform bacteria was significantly above the pre-
antibiotic level indicating increased growth and colonisation of these groups in the period
immediately after the antibiotic course. 180 days after the antibiotic course, both the total bac-
terial counts and the 3 specific bacterial groups had returned to the same levels as prior to the
antibiotic treatment.
Antibiotics were measurable in day 4 faecal samples from all participants indicating compli-
ance to the antibiotic prescription.
Postprandial plasma glucose excursions and serum insulin responses
No change in fasting serum insulin or C-peptide concentration, tAUCglucose, tAUCinsulin,
tAUCC-peptide, HOMA, Matsuda, insulinogenic or disposition indices were observed between
baseline and day 4 or 42 (Table 2 and Fig 3). However, there was a tendency (p = 0.05) towards
a slightly reduced tAUCinsulin on day 4.
Postprandial plasma gut hormone responses
No change in basal or postprandial (tAUC) concentrations of the gut hormones gastrin, CCK,
GIP or GLP-1 was observed from day 0 to 4 or 42 (Table 2). In contrast, tAUCPYY increased by
Table 1.
Day 0 95% CI Day 4 95% CI Day 8 95% CI Day 42 95% CI Day 180 95% CI
Bodyweight (kg) 78.1 (73.9–82.4) 78.2 (76.4–78.7) 77.6 (76.4–78.7) 77.7 (76.5–78.9) 79.4† (78.2–80.6)
BMI (kg/m2) 22.6 (21.3–23.8) 22.6 (22.1–22.7) 22.4 (22.1–22.7) 22.4 (22.1–22.8) 22.9† (22.6–23.3)
Glucose (mmol/l) 5.09 (4.91–5.28) 5.11 (4.99–5.24) - 5.21 (5.09–5.34)
HbA1c (mmol/mol) 32 (31–33) - - 31 (30–32) 32 (31–33)
HbA1c (%) 5.08 (4.96–5.20) 5.00 (4.88–5.11) 5.06 (4.94–5.17)
Cholesterol (mmol/l) 3.6 (3.3–4.1) 3.6 (3.4–3.9) 3.9† (3.7–4.2) 3.6 (3.4–3.9) 3.9† (3.7–4.2)
LDL (mmol/l) 1.9 (1.6–2.3) 1.9 (1.8–2.2) 2.2† (2.0–2.5) 1.9 (1.7–2.1) 2.2† (2.0–2.4)
HDL (mmol/l) 1.1 (1.0–1.2) 1.1 (1.0–1.2) 1.2 (1.1–1.3) 1.1 (1.0–1.1) 1.1 (1.0–1.2)
VLDL (mmol/l) 0.6 (0.4–0.8) 0.5 (0.4–0.7) 0.5 (0.4–0.6) 0.5 (0.4–0.7) 0.5 (0.4–0.7)
Triglyceride (mmol/l) 1.2 (0.9–1.6) 1.2 (0.9–1.5) 1.0 (0.8–1.3) 1.2 (0.9–1.5) 1.1 (0.9–1.5)
CRP (mg/l) 0.4 (0.2–0.7) 0.3 (0.1–0.7) 0.4 (0.2–0.8) 0.6 (0.3–1.4) 0.5 (0.2–1.1)
Bodyweight, body mass index (BMI), blood concentration of glycated haemoglobin (HbA1c) and plasma concentration of glucose, cholesterol, low-density
lipoprotein (LDL), high-density lipoprotein (HDL), very-low-density lipoprotein (VLDL), triglyceride and C-reactive protein (CRP) measured in the fasting
state on each of the 5 study days. Data are expressed as mean (geographical mean for log-transformed data) and 95% conﬁdence intervals (CI) in
brackets.
† denotes p<0.05, indicating a signiﬁcant change compared to day 0.
doi:10.1371/journal.pone.0142352.t001
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40% from day 0 to day 4, whereas no change in tAUCPYY was found from baseline to day 42
(Table 2 and Fig 4).
Gastric emptying, gallbladder emptying, appetite, food intake and basal
metabolic rate
No change in resting metabolic rate, composite appetite score or ad libitum food intake was
found between day 0, 4 and 42 (S1 Table). No significant change in gall bladder volume at any
Fig 2. Abundance of faecal bacteria expressed asmeans (±standard error of the mean) of log10-transformed number of colony forming units (CFU)
per gram of faeces upon cultivation. The dotted line shows the lower detection limit. Reductions were observed in the abundance of faecal anaerobes,
coliform, enterococci and bifidobacteria from day 0 to day 4. At 180 days after the antibiotics course, both the total aerobic and total anaerobic bacterial
counts as well as the 3 specific bacterial groups had returned to the same levels as prior to the antibiotics course.
doi:10.1371/journal.pone.0142352.g002
Table 2.
Day 0 Day 4 95% CI Day 42 95% CI
Glucose 1 0.98 (0.95–1.01) 1.00 (0.97–1.04)
Insulin 1 0.85 (0.73–1.00) 1.06 (0.90–1.24)
C-peptide 1 0.90 (0.81–1.00) 1.03 (0.93–1.15
Gastrin 1 1.07 (0.94–1.22) 0.95 (0.84–1.09)
CCK 1 0.97 (0.86–1.10) 0.97 (0.86–1.10)
GIP 1 1.06 (0.92–1.22) 1.09 (0.94–1.25)
GLP-1 1 1.05 (0.75–1.48) 1.20 (0.85–1.68)
PYY 1 1.40† (1.20–1.63) 1.08 (0.92–1.25)
Relative changes in postprandial plasma/serum excursions of glucose, pancreatic and gut hormones on day 4 and 42 expressed as mean change in total
area under curve (tAUC) with day 0 as reference (with 95% conﬁdence intervals (CI) in brackets), e.g. tAUCPYY increased 40% from day 0 to day 4.
† denotes p<0.05. CCK, cholecystokinin, GIP, glucose-dependent insulinotropic polypeptide, GLP-1, glucagon-like peptide-1, PYY, peptide YY.
doi:10.1371/journal.pone.0142352.t002
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of the 5 time points (-15, 25, 55, 90 and 235 min) on day 0, 4 and 42 were found and no signifi-
cant changes in time-to-peak plasma paracetamol concentration were seen (S1 Table).
Discussion
We report that a short-term broad-spectrum antibiotic course in healthy young males results
in 1) acute and dramatic reductions in the abundance of a representative set of gut bacteria
confirmed by cultivation of faecal samples, 2) acutely and reversibly increased circulating
PYY3-36 concentrations, but 3) no changes in glucose tolerance or release of gastrin, CCK,
GIP and GLP-1.
Although substantial changes in metabolic phenotype has been previously seen in animals
exposed to antibiotics [36–38], few human interventional studies have investigated the effect of
antibiotic treatment on gut hormone secretion or glucose metabolism. In a Dutch study, 20
obese patients with metabolic syndrome were randomised to receive 7 days of per oral treat-
ment with either vancomycin (500 mg thrice-daily) or amoxicillin (500 mg thrice-daily) [16].
Mixed meal tests performed before and immediately after the treatment period showed no
changes in postprandial glucose tolerance or secretion of the gut-derived incretin hormones
Fig 3. Mean (±standard error of the mean) postprandial excursions of plasma glucose, insulin and C-peptide on day 0, 4 and 42. No significant
change in postprandial plasma glucose, insulin or C-peptide responses (assessed as area under curve) was observed.
doi:10.1371/journal.pone.0142352.g003
Fig 4. Mean (±standard error of the mean) postprandial excursions of plasma gastrin, cholecystokinin (CCK), glucose-dependent insulinotropic
polypeptide (GIP), glucagon-like-peptide 1 (GLP-1) and peptide YY (PYY) on day 0, 4 and 42. An acute reversible increase in plasma PYY concentration
was seen following the antibiotics course, whereas no significant changes were seen in the plasma concentrations of the other gut hormones.
doi:10.1371/journal.pone.0142352.g004
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GIP and GLP-1, but hyperinsulinaemic euglycaemic clamps showed a slight decrease in
peripheral insulin sensitivity in the group receiving vancomycin compared to no change in the
amoxicillin group. In contrast, a recent follow-up to this study showed no difference in insulin
sensitivity following vancomycin or amoxillin compared to placebo treatment in obese males
with impaired glucose tolerance [39]. In line with the latter, we found no change in tAUCinsulin,
tAUCC-peptide or HOMA, Matsuda or insulinogenic indices between study days in the present
study with a 4 day-duration of antibiotics intervention.
The gut microbiota has been suggested to affect host glucose metabolism by at least 4 different
mechanisms: Through modulation of the bile acid pool [16,40], stimulation of the innate
immune system [41], or by fermentation of complex carbohydrates to short-chain fatty acids
that can either function directly as metabolic substrates or influence the secretion of gut hor-
mones [42]. Regarding the first 2 mechanisms, we did not find any change in gallbladder volume
or emptying, and we saw no changes in CRP. In relation to the latter mechanism it was recently
reported that germ-free rodents with low intestinal levels of short-chain fatty acids had higher
expression of proglucagon, higher GLP-1 levels and higher density of enteroendocrine L cells, the
cell responsible for secretion of GLP-1 as well as PYY [43]. The high GLP-1 secretion was abol-
ished upon bacterial colonisation of the germ free animals, but could be re-established by subject-
ing conventionally raised rodents to a short course of broad-spectrum antibiotics expected to
eradicate most of the gut bacteria [43]. Although PYY has well-established effects on appetite
sensation and food intake, a direct effect of PYY on glucose metabolism remains controversial
[44]. Increased secretion of PYY has previously been reported in patients with diarrhoea follow-
ing gastrointestinal infection [45] and an important function of PYYmay be to limit nutrient
and water excretion by reducing colonic transit time and fluid secretion [46,47]. In our study,
several participants reported diarrhoea during the antibiotic course, and after completion of the
course, plasma PYY concentrations were increased. It might therefore be hypothesised that the
increased PYY secretion is a physiologic response to limit water and nutrient loss following (anti-
biotic-induced) diarrhoea. We saw a decrease in faecal abundance of short-chain fatty acid pro-
ducing genera (bifidobacteria) [48] at the same time that plasma concentrations of PYY went up,
raising the question of the role of short-chain fatty acids for this response. However, the general
belief is that short-chain fatty acids stimulate L cell secretion [49] and perhaps it is rather
increased exposure of the L cells with loose stool fluid containing other L cell stimulants (unab-
sorbed nutrients or bile acids), that is responsible for the increased PYY secretion.
Several limitations of the current study should be addressed. Firstly, as we did not include
an untreated comparison group, we cannot rule out random variation or study effects as expla-
nations for the negative results or the observed differences between baseline and subsequent
study days. The finding of a small increase in bodyweight on day 180 is in line with observa-
tional studies reporting long-term increased risk of obesity following antibiotics [11,12,15,50],
but could also reflect aging of the participants or seasonal variation [51]. The findings of
increased plasma cholesterol concentrations on day 8 and 180, with no changes on day 4 and
42 are not supported by previous studies, do not seem biologically meaningful and may result
from natural variation and/or slight deviations in study procedures on day 8 and 180 compared
to day 0, 4 and 42 (see methods). Secondly, the low participant number means a low statistical
power for detecting small changes. However, the confidence intervals of the observed variables
(Table 1 and Table 2) were generally narrow, indicating that we did not ignore a clinically rele-
vant metabolic difference. Thirdly, for ethical reasons, considering the risk of antibiotic resis-
tance development and the lack of knowledge about metabolic effects of antibiotics at the time
of the study initiation, we chose to employ a short-term antibiotics course. Although this anti-
biotics course indeed led to dramatic acute changes in microbiota load and composition, we
cannot exclude the possibility that other antibiotic courses could induce even more dramatic
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effects on the gut microbiota, and subsequently could have more pronounced or sustained met-
abolic effects. This possibility seems particularly plausible if antibiotics are given multiple
times, in higher dosages or during critical periods of life such as early life [12,38,50]. Lastly,
although we found no long-term changes in the abundance of several common gut bacterial
groups, it is important to emphasize that compositional changes at the phylum, genus or spe-
cies level will not be detected by the applied cultivation technique, nor did our investigation
assess if metabolically relevant changes occurred in the gut microbiome.
Interestingly, we observed an increase in faecal abundance of several bacterial groups sub-
acutely following antibiotics, which is in line with a recent human study using qPCR to assess
changes in gut microbiota following antibiotic treatment [9]. A likely explanation is that the
increased bacterial groups have occupied new ecological niches in the gut, which were made
available by the antibiotic treatment.
Conclusion and Future Directions
An acute reversible increase in the postprandial plasma level of the gut hormone PYY, but no
clinically relevant changes in insulin sensitivity, insulin release or release of other gut hormones
were seen following 4-day broad-spectrum antibiotics course in healthy young males. There
was an apparent lack of association between substantial shifts in gut microbiota as evaluated by
cultivation and overall unchanged metabolic variables, contrasting the current dogma, which
implies the gut microbiota to be a key player in metabolic regulation. However, sustained or
pronounced metabolic effects of antibiotics given in other dosages or to other populations can-
not be excluded based on this study. In a recent population-based case-control study, exposure
to narrow-spectrum antibiotics was more strongly associated with development of type 2 dia-
betes, than exposure to general or broad-spectrum antibiotics [13]. Data on the long-term met-
abolic effect of commonly used narrow-spectrum antibiotics (such as
phenoxymethylpenicillin) therefore seems warranted.
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